Skip to main content
Maurizio Fava, MD, Psychiatry, Boston, MA, Massachusetts General Hospital

MaurizioFavaMD

Psychiatry Boston, MA

Psychopharmacology

Psychiatrist-in-Chief, Massachusetts General Hospital (MGH), Director, Division of Clinical Research of the MGH Research Institute; Slater Family Professor of Psychiatry, Harvard Medical School; Executive Director, MGH Clinical Trials Network and Institute

Dr. Fava is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fava's full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital/McLean Hospital
    Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1985 - 1988
  • University of Padua College of Medicine
    University of Padua College of MedicineClass of 1982

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 1984 - 2026
  • MA State Medical License
    MA State Medical License 1988 - 2025
  • American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • Top MD Consumers Checkbook

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Research Paper Tachyphylaxis in Major Depressive Disorder: A Review of the Current State of Research  
    Gustavo Kinrys, Andrew A Nierenberg, George I Papakostas, David Mischoulon, Maurizio Fava, Marlene P Freeman, ScienceDirect
  • Can Electronic Health Records Revive Central Nervous System Clinical Trials?  
    Maurizio Fava, Roy H Perlis, Nature
  • Research Paper Understanding the Effects of Emotional Reactivity on Depression and Suicidal Thoughts and Behaviors: Moderating Effects of Childhood Adversity and Resil...  
    Benjamin G Shapero, Daphne J Holt, Amy Farabaugh, Joey C Cheung, Maurizio Fava, ScienceDirect
  • Join now to see all

Lectures

  • Strategies for the Treatment of Anxious Depression 
    162nd Annual Meeting, San Francisco, California, USA
  • Strategies for the Treatment of Anxious Depression 
    American Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA

Authored Content

  • S131. Resting State Functional Connectivity Patterns Differentially Predict Treatment Outcomes to Sertraline Versus Placebo in Patients with Major Depressive DisorderApril 2018
  • S131. Resting State Functional Connectivity Patterns Differentially Predict Treatment Outcomes to Sertraline Versus Placebo in Patients with Major Depressive DisorderApril 2018
  • S132. Cerebral Blood Perfusion Predictors of Antidepressant Response in Major Depressive DisorderApril 2018
  • S132. Cerebral Blood Perfusion Predictors of Antidepressant Response in Major Depressive DisorderApril 2018
  • Characterizing Anxiety Subtypes and the Relationship to Behavioral Phenotyping in Major Depression: Results from the EMBARC StudyApril 2018
  • Characterizing Anxiety Subtypes and the Relationship to Behavioral Phenotyping in Major Depression: Results from the EMBARC StudyApril 2018
  • Join now to see all

Press Mentions

  • ABVC BioPharma Provides 2023 Pipeline Update
    ABVC BioPharma Provides 2023 Pipeline UpdateFebruary 28th, 2023
  • Relmada’s MDD Drug Misses Endpoint, Marred by “Paradoxical Results”
    Relmada’s MDD Drug Misses Endpoint, Marred by “Paradoxical Results”October 13th, 2022
  • Relmada Therapeutics Announces Top-Line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
    Relmada Therapeutics Announces Top-Line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive DisorderOctober 13th, 2022
  • Join now to see all

Professional Memberships

Other Languages

  • Italian

Hospital Affiliations